報價延遲最少15分鐘:2025/01/11 11:20 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.84/-0.82
|
|
企業價值
308.80M
|
| 資產負債 |
|
每股賬面淨值
0.27
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
90.12M
|
|
每股收益
0.48
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/11 11:20 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255). |